Lung cancer

Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
Wickramasinghe, B., Renzi, C., Barclay, M., Callister, M. E. J., Rafiq, M., & Lyratzopoulos, G. (2023). Pre-diagnostic prescribing patterns in dyspnoea patients with as-yet-undiagnosed lung cancer: A longitudinal study of linked primary care and cancer registry data. Cancer Epidemiol, 86, 102429. http://doi.org/10.1016/j.canep.2023.102429
van Veelen, A., Abtahi, S., Souverein, P., Driessen, J. H. M., Klungel, O. H., Dingemans, A. C., et al. (2022). Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiol, 78, 102149. http://doi.org/10.1016/j.canep.2022.102149